Takara Bio Inc
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for… Read more
Takara Bio Inc (TF2) - Net Assets
Latest net assets as of September 2025: €102.65 Billion EUR
Based on the latest financial reports, Takara Bio Inc (TF2) has net assets worth €102.65 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€131.85 Billion) and total liabilities (€29.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €102.65 Billion |
| % of Total Assets | 77.85% |
| Annual Growth Rate | 6.64% |
| 5-Year Change | 55.92% |
| 10-Year Change | 92.73% |
| Growth Volatility | 8.64 |
Takara Bio Inc - Net Assets Trend (2014–2025)
This chart illustrates how Takara Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Takara Bio Inc (2014–2025)
The table below shows the annual net assets of Takara Bio Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €115.85 Billion | +3.64% |
| 2024-03-31 | €111.78 Billion | -0.60% |
| 2023-03-31 | €112.45 Billion | +17.06% |
| 2022-03-31 | €96.06 Billion | +29.29% |
| 2021-03-31 | €74.30 Billion | +11.58% |
| 2020-03-31 | €66.59 Billion | +3.89% |
| 2019-03-31 | €64.09 Billion | +3.45% |
| 2018-03-31 | €61.96 Billion | +3.29% |
| 2017-03-31 | €59.98 Billion | -0.21% |
| 2016-03-31 | €60.11 Billion | +0.78% |
| 2015-03-31 | €59.64 Billion | +4.40% |
| 2014-03-31 | €57.13 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Takara Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 620.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €52.47 Billion | 45.43% |
| Other Components | €63.03 Billion | 54.57% |
| Total Equity | €115.50 Billion | 100.00% |
Takara Bio Inc Competitors by Market Cap
The table below lists competitors of Takara Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Primis Financial Corp
NASDAQ:FRST
|
$278.81 Million |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
$278.82 Million |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
$278.86 Million |
|
Tianjin Jiuri New Materials Co Ltd
SHG:688199
|
$278.88 Million |
|
APG SGA SA
SW:APGN
|
$278.75 Million |
|
Hunan Resun Co Ltd
SHE:001218
|
$278.75 Million |
|
ASRock Inc
TW:3515
|
$278.75 Million |
|
Jiangsu Holly Corp
SHG:600128
|
$278.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Takara Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 111,503,000,000 to 115,498,000,000, a change of 3,995,000,000 (3.6%).
- Net income of 1,041,000,000 contributed positively to equity growth.
- Dividend payments of 2,048,000,000 reduced retained earnings.
- Other factors increased equity by 5,002,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.04 Billion | +0.9% |
| Dividends Paid | €2.05 Billion | -1.77% |
| Other Changes | €5.00 Billion | +4.33% |
| Total Change | €- | 3.58% |
Book Value vs Market Value Analysis
This analysis compares Takara Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €497.30 | €6.05 | x |
| 2018-03-31 | €513.64 | €6.05 | x |
| 2019-03-31 | €531.56 | €6.05 | x |
| 2020-03-31 | €552.20 | €6.05 | x |
| 2021-03-31 | €616.03 | €6.05 | x |
| 2022-03-31 | €796.17 | €6.05 | x |
| 2023-03-31 | €931.91 | €6.05 | x |
| 2024-03-31 | €925.98 | €6.05 | x |
| 2025-03-31 | €959.16 | €6.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Takara Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.31%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.09x
- Recent ROE (0.90%) is below the historical average (6.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 2.58% | 6.15% | 0.38x | 1.10x | €-4.24 Billion |
| 2015 | 1.62% | 3.71% | 0.39x | 1.12x | €-4.99 Billion |
| 2016 | 2.22% | 4.49% | 0.45x | 1.11x | €-4.67 Billion |
| 2017 | 2.26% | 4.60% | 0.44x | 1.12x | €-4.64 Billion |
| 2018 | 3.78% | 7.23% | 0.47x | 1.11x | €-3.85 Billion |
| 2019 | 5.71% | 10.20% | 0.50x | 1.11x | €-2.74 Billion |
| 2020 | 5.74% | 11.05% | 0.46x | 1.13x | €-2.83 Billion |
| 2021 | 12.87% | 20.72% | 0.51x | 1.21x | €2.13 Billion |
| 2022 | 20.70% | 29.32% | 0.59x | 1.21x | €10.26 Billion |
| 2023 | 14.27% | 20.49% | 0.60x | 1.15x | €4.79 Billion |
| 2024 | 1.33% | 3.40% | 0.36x | 1.09x | €-9.67 Billion |
| 2025 | 0.90% | 2.31% | 0.36x | 1.09x | €-10.51 Billion |
Industry Comparison
This section compares Takara Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Takara Bio Inc (TF2) | €102.65 Billion | 2.58% | 0.28x | $278.76 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |